Articles tagged with Ovarian Tumors
Researchers developed a novel personalized vaccine made from tumor tissue and immune cells, inducing potent immune responses in patients with recurrent ovarian cancer. The vaccine showed promise in extending overall survival and improving progression-free survival.
Researchers have developed a universal fluorescent probe that targets and stains cancer stem cells, a type of tumor-initiating cell. The probe, named TiY, demonstrates high selectivity towards these cells, which are believed to cause relapses after radiation and chemotherapy.
Researchers developed a new method to identify highly reactive killer T cells in ovarian tumors, showing they can be selectively grown for personalized cell-based immunotherapies. The approach overcomes limitations of existing methods, enabling the use of tumor-infiltrating lymphocytes for treating low-mutational load tumors.
Researchers at Rice University and MD Anderson Cancer Center use fluorescent carbon nanotube probes to locate specific tumors in the body. The noninvasive technique achieved first in vivo success in detecting small concentrations of nanotubes inside rodents with high accuracy.
A recent study led by Mayo Clinic researchers found that tumor-infiltrating lymphocytes present in high-grade ovarian cancer tumors can predict patient survival. The study analyzed over 5,500 patients from nine countries and discovered that higher levels of these immune cells were associated with better outcomes.
A study found that patients with one normal BRCA gene and germline mutations in breast and ovarian cancers had better survival rates when treated with chemotherapy. The research team evaluated the genetic profiles of 160 tumors and discovered a relationship between BRCA gene retention and resistance to treatment. Patients with normal B...
In preclinical studies, tumors with constitutive IDO1 expression responded to COX-2 inhibitor celecoxib and improved T-cell infiltration, making them more likely to respond to anti-PD1 therapies. COX-2 inhibitors may reverse IDO1-mediated immunosuppression in some cancers.
A team of researchers at Fred Hutchinson Cancer Center will use recent technological advances in proteogenomics to identify biomarkers predicting treatment response and novel therapeutic targets for ovarian cancer. The goal is to improve understanding of drug resistance and ultimately enhance patient outcomes.
Researchers found that continuous, low-dose cisplatin delivery is effective against smaller tumor clusters, while higher doses are more effective against larger ones. The study's findings support the development of an implantable device to deliver these higher doses without the side effects associated with current catheter-based therapy.
Researchers have identified a new combination therapy that may improve survival for women with ovarian cancer by eradicating chemotherapy-resistant tumors. The treatment, involving carboplatin and birinapant, showed promise in mice and human tumor models, with 50% of samples responding to the therapy.
Researchers have developed a new test that can detect ovarian cancer months earlier than current methods, potentially improving five-year survival rates. The test uses synthetic biomarkers that interact with tumor proteins to release fragments in urine samples.
Researchers have developed a new method to diagnose cancer using ultrasound and microbubbles that can identify malignant tumors with high accuracy. The technique has shown promise in distinguishing between benign and malignant breast and ovarian tumors, potentially reducing unnecessary surgeries.
A new study reveals that inhibiting AXL signaling increases anti-tumor immune response, sensitizes tumors to radiation, and enhances efficacy of anticancer therapies. Aravive-S6 acts as a decoy receptor, binding Gas-6 to prevent AXL activation.
Researchers found correlations between circulating tumor DNA (ctDNA) levels and ovarian cancer size, as well as patient response to treatment. The study used ctDNA carrying mutations in the TP53 gene to predict disease progression and treatment response, offering potential for early diagnosis and alternative treatment options.
Researchers found that female sex hormones activate immune cells, damaging nerves necessary for vision in children with a rare genetic disorder. Blocking these hormones or suppressing specific immune cells may help save eyesight.
Researchers at Rice University have discovered that a diabetes drug can halt the production of glycoproteins that make up the protective mucus lining cells, allowing immune cells to target tumors. The study suggests that reducing mucin levels may be enough to breach the tumor's protective shield and allow for cancer cell destruction.
Researchers at Stanford University School of Medicine developed a receptor that attracted a key cancer-causing molecule called Gas6, slowing the progression of pancreatic and ovarian cancer in mice. The 'decoy receptor' showed a higher ability to reduce or stop cancer growth than other treatments did.
Scientists at The Wistar Institute discovered how MEK inhibitor trametinib controls tumor progression by reducing immune suppression and allowing anti-tumor T cells to target tumors. This finding provides new insights into the effects of targeted therapies on antitumor immunity.
The ESMO-MCBS scale has been successfully applied to rare tumor entities, revealing its potential to quantify the clinical benefit of certain drugs. The tool was particularly effective in highlighting the benefits of new immunomodulatory treatments.
Researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas, pointing to possible new treatments. The study identified key mutations in cancer genes that may explain the mixed tissue characteristics of these tumors.
Researchers at The Wistar Institute have identified a specific receptor-protein expressed on the surface of ovarian tumor cells, offering a highly targeted therapeutic target for immunotherapy. This technology uses chimeric endocrine receptor-expressing T-cells to selectively eliminate cancerous cells with minimal adverse effects.
Researchers identified specific parasite proteins that trigger an antitumor immune response in mice with ovarian tumors. The discovery could lead to the development of new therapies using Toxoplasma gondii, a parasite that has been shown to cure mice of solid tumors.
Researchers at Mayo Clinic developed a new method to detect ovarian cancer recurrence using liquid biopsies from blood tests and DNA sequencing. This approach allows for earlier intervention and more effective individualized treatment by monitoring genetic changes in circulating cell-free DNA.
Researchers developed nanoparticles that target and deliver chemotherapy drugs to metastatic cancer tumors using radiation guidance. The approach exploits overexpression of P-selectin molecules in human cancers, allowing for selective tumor penetration.
A new fluorescent agent and imaging system guided surgeons in real-time to remove additional ovarian tumors that were not visible without fluorescence or could not be felt during surgery. This improved visualization allowed for the detection of an additional 29% of malignant lesions.
Researchers discover small peptides psaptides that can force tumors to regress by stimulating an anti-angiogenic response in healthy tissues. Psaptides mimic the naturally occurring human protein prosaposin, which stimulates immune cells to produce a potent anti-inflammatory protein called thrombospondin-1.
Researchers at KU Leuven have fine-tuned a test for ultrasound diagnosis of ovarian tumours, improving accuracy and providing exact risk assessments. The new test has been analysed in 5,000 patient cases from 22 countries and is now ready for clinical use.
A plant virus shell triggers a potent immune response in mice, wiping out tumors and preventing metastatic disease. The treatment, using cowpea mosaic virus nanoparticles, shows promise as an effective and low-toxicity alternative to traditional therapies.
Researchers at the University of Cambridge have developed a non-invasive blood test that can diagnose some types of malignant childhood tumour with high accuracy. The test looks for specific genetic code patterns in blood and cerebrospinal fluid samples, allowing for early diagnosis and monitoring without exposure to radiation.
Researchers found that losing CD73 enzyme promotes tumor growth and progression in endometrial cancer by disrupting adenosine signaling, which normally regulates tissue function. The study provides new insights into the role of CD73 in cancer development.
Studies show that having one child reduces the risk of certain types of ovarian cancer, such as serous, mucinous, endometrioid, and clear cell tumours. Women who have had their fallopian tubes cut or clipped also experience a lower risk of developing these cancers.
Research on biodegradable nanomedicine shows promise in selectively destroying ovarian cancer cells left behind after surgery. The technology uses nanoparticles to provide real-time imaging and phototherapy treatment during surgery, achieving complete tumor eradication in mice with no adverse effects.
PharmaMar has initiated a multicenter, international phase II Basket trial to evaluate the efficacy and safety of PM1183 (lurbinectedin) in patients with various advanced solid tumors. The trial will assess the overall response rate, duration of response, and pharmacokinetic properties of the drug.
A modified version of a protein that suppresses female reproductive organ development has been shown to inhibit the growth of chemotherapy-resistant ovarian tumors in animal models. Researchers at Massachusetts General Hospital have developed a gene therapy approach using a viral vector to deliver this protein, which resulted in signif...
A special issue of Immunotherapy explores emerging concepts in adoptive cell immunotherapy (ACT) to extend its effects to a wider range of solid and hematological cancers. The journal reviews new strategies to address challenges and potentially improve treatment options for more cancer types.
The myChoice HRD test predicts response to DNA-damaging agents in ovarian, breast, and pancreatic cancers. A score of ?42 indicates a loss of DNA repair function and reflects tumor sensitivity to PARP inhibitors and platinum-based therapies.
Researchers at the University of Notre Dame investigate the clinical potential of microvesicles, shedding light on their role in promoting tumor invasion and metastasis. The study identifies key proteins that guide the formation of these vesicles and suggests a potential link to biomarker development.
Researchers at the University of Utah Health have discovered patterns in DNA anomalies that predict a woman's outcome significantly better than tumor stage, also indicating how well she'll respond to platinum therapy. The new method could lead to personalized prognostic and diagnostic laboratory tests.
The Anderson Algorithm increases surgical success in advanced ovarian cancer by providing a personalized approach to surgery, resulting in high complete resection rates of over 86%. This milestone is strongly tied to improved survival outcomes for patients.
Researchers developed a customized genetic construct using tiny DNA minicircles to detect cancer in mice. The technique uses a protein called secreted embryonic alkaline phosphatase, which is not produced in adults but is present in embryos.
Researchers discovered a new way to shrink ovarian cancer tumors by inhibiting abnormal angiogenesis. Using a naturally occurring protein inhibitor called 3TSR, the approach improved chemotherapy drug delivery and resulted in significant tumor regression and survival.
Researchers at the University of Helsinki identified an alternative cell pathway promoting blood vessel growth that may explain why certain cancer therapies are failing to improve patient survival. This discovery could help clarify confusing trial results and potentially lead to new treatments for ovarian cancer and other cancers.
Researchers developed new animal models that faithfully reproduce the evolution and malignancy of different human tumors. This allows for parallel tumor progression, prediction of relapses, and assessment of effective treatments in a controlled laboratory setting.
A study by The Wistar Institute found that a polymorphism in the TLR5 gene affects tumor progression and inflammation in breast and ovarian cancers. In individuals with functional TLR5 expression, commensal bacteria stimulate IL-6 production, leading to suppressed antitumor immune activity.
Researchers found that too much Rbm38 reduces p53 levels, increasing cancer risk, while too little Rbm38 causes premature aging. The study suggests manipulating Rbm38 could have therapeutic benefits by targeting p53 in tumor cells.
A novel combination therapy using low-dose chemotherapy with an antiangiogenic treatment, 3TSR, improved survival rates in an animal model of ovarian cancer. The treatment resulted in tumor regression, improved blood flow, and more efficient delivery of chemotherapy drugs with reduced side effects.
Researchers at University of Guelph found a potential breakthrough in treating late-stage ovarian cancer by shrinking tumours and improving drug delivery. This approach may lead to novel treatment options with reduced morbidity and mortality.
Researchers discovered that simvastatin inhibits the growth of uterine fibroid tumors, which are responsible for half of all hysterectomies. The study found that simvastatin impedes cell growth and induces calcium-dependent cell death mechanisms in fibroid tumor cells.
Researchers have discovered that tumor cells secrete exosomes containing proteins capable of transforming neighboring cells into tumor cells, promoting tumor growth. Dicer protein is identified as a key factor in this process and may serve as a biomarker or therapeutic target.
Researchers developed a new test called ADNEX to accurately diagnose ovarian tumours and choose the most appropriate treatment. The test uses clinical information, tumour marker blood tests, and ultrasound scan features to discriminate between benign and malignant tumours with high accuracy.
A study by Myriad Genetics presented at the 2014 European Society for Medical Oncology (ESMO) annual meeting shows that its Tumor BRACAnalysis CDx test identifies cancer-causing BRCA1/2 mutations in 44% more patients than germline blood testing. This could expand treatment options for ovarian cancer patients with these genetic mutations.
Researchers at Kiel University discovered primordial cancer in a primitive animal, Hydra, which provides crucial information to understand complex problems like cancer. The study confirms that tumours exist in evolutionary old animals and affect only female Hydra polyps, resembling ovarian cancers in humans.
A novel DNA vaccine targets TEM1, a protein overexpressed in tumors, reducing tumor vascularization and increasing immune cell infiltration. The vaccine induces epitope spreading, creating a secondary immune response against the tumor itself.
Scientists have identified a set of proteins called TAFs that may play a role in the development of ovarian cancer. Studies found that these proteins are overexpressed or underexpressed in 73% of tumors, suggesting they could be potential targets for new treatments.
A new cancer vaccine has demonstrated prolonged survival in animal models of both tumors by stimulating the immune system to attack cancer cells. The vaccine combines a molecule targeting a tumor-cell-surface antigen with another protein that stimulates several immune functions.
A University of Colorado study used a COXEN model to match tumors with optimal drugs, significantly extending patient survival. The model analyzed genetic data from thousands of tumor samples to identify response patterns.
Scientists at Fred Hutchinson Cancer Center developed a method to count tumor-infiltrating T lymphocytes reliably and quickly, which correlates with improved survival rates. The technology has the potential to predict treatment response, cancer recurrence, and disease-free survival earlier and more effectively.
A comprehensive study reveals unprecedented genetic variation in ovarian cancer, highlighting potential new pathways for therapeutic intervention. The research suggests that sampling and sequencing of multiple disease sites may be required for effective targeted treatments.
Researchers have discovered a key protein called LIN28 that triggers malignant germ cell tumors, a type of cancer affecting the testes and ovaries. By targeting this protein, scientists hope to develop new therapies with less severe side effects.
Researchers found that macrophages are essential for embryo implantation in the uterus. The absence of these cells leads to reduced hormone levels, causing embryos to fail to implant. Restoration of macrophage function or hormone replacement therapy can revive pregnancy, shedding new light on a potential cause of infertility.